Randy Osborne is a writer/editor for Deloitte Recap LLC. He worked with BioWorld for more than 11 years, and has contributed to Nature Biotechnology and other publications.
Despite cancer’s complex nature, biotech firms have cranked out approvable therapies for the disease at an impressive pace, from blockbusters such as Genentech/Roche’s bevacizumab (Avastin) and trastuzumab (Herceptin) to smaller-selling but... Read more »